Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · LeMaitre Vascular (LMAT)

LeMaitre Q2 sales rise 11% to $55.8 million; profit up 46%, full-year guidance raised

Positive Impact 4 of 5 guidance Written later

LeMaitre Vascular reported preliminary second-quarter 2024 results, with sales of $55.8 million, up 11% from a year earlier, and net income of $11.8 million, up 46%. The company raised its full-year 2024 guidance, now projecting sales of $216.8 million to $220.8 million and EPS of $1.82 to $1.91, which shareholders will weigh alongside the company's higher quarterly profitability.

Key points

  • Q2 2024 sales $55.8 million, up 11% (12% organic); diluted EPS $0.52, up 44%
  • Gross margin 68.9%, up from 64.0% in Q2 2023; operating income $14.4 million, up 52%
  • Full-year 2024 guidance: sales $216.8 million to $220.8 million; EPS $1.82 to $1.91
  • Quarterly dividend of $0.16 per share payable August 29, 2024, to holders of record August 15, 2024

The filing

CompanyLeMaitre Vascular (LMAT)
Form8-K, current report
Filed with the SECAug 1, 2024, 4:26 PM ET
Accession number0001437749-24-024304

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 01, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.